Glaxo projects sales boost from shingles vaccine

GlaxoSmithKline (GSK) forecast that 2019 sales of its shingles vaccine would be more than £1bn (€1.1bn) but the drugmaker’s shares slipped on concerns about its pharmaceutical business and free cash flow.

Shingrix, the shingles vaccine launched in 2017, is an important source of growth for chief executive Emma Walmsley, as she strives to improve GSK’s commercial performance after streamlining its operations and spinning off or selling units.